Zheng, Shuai
Shao, Feng
Ding, Yu
Fu, Zhenzhen
Fu, Qi
Ding, Sijia
Xie, Lijun
Chen, Juan
Zhou, Sufeng
Zhang, Hongwen
Zhou, Hongwen
Chen, Yang
Sun, Caixia
Zhu, Jing
Zheng, Xuqin
Yang, Tao http://orcid.org/0000-0001-6375-3622
Funding for this research was provided by:
Yabao Pharmaceutical R&D Co., Ltd.
Article History
Accepted: 18 September 2020
First Online: 30 October 2020
Declarations
:
: This study was funded by Yabao Pharmaceutical R&D Co., Ltd.
: Globalagliatin was originally developed by Eli Lilly and Company and later licensed out to Yabao for clinical development. There are no other potential conflicts of interest relevant to this study.
: All procedures in this study were in accordance with the 1964 Helsinki Declaration (and its amendments), and approved by the appropriate institutional review boards and regulatory agencies.
: All participants provided written informed consent prior to inclusion.
: The datasets obtained and/or analyzed during the current study are available from the corresponding author on reasonable request.